Novartis

Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
Novartis

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...
Novartis

Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK ...

We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and ...
Novartis

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress on June 3, 2026.²˒⁹ “People living with PMR need treatments that provide lasting remission, ...
Novartis

25 years of expanding access to cancer care

Cancer care has seen remarkable progress, but that progress has not been felt equally everywhere. Novartis and The Max Foundation have worked to change that. Together, since 2001, we have expanded ...
Novartis

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in ...
Novartis

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing ...
Novartis

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

East Hanover, July 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta ® (iptacopan) to slow kidney function decline in ...
Novartis

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settings Basel, July 6, 2026 - Novartis today ...
Novartis

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, ...
Novartis

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs 1 Clinically relevant 15.2% ...
Novartis

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...